Phosphatidylinostol 3-kinase mediates angiogenesis and vascular permeability associated with ovarian carcinoma

Clinical Cancer Research

Volumn 11, Issue 22, 2005, Pages 8208-8212

  Hu, Limin ^a   Hofmann, Judith ^a   Jaffe, Robert B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; PHOSPHATIDYLINOSITOL 3 KINASE; VASCULOTROPIN; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CHROMONE DERIVATIVE; ENZYME INHIBITOR; MORPHOLINE DERIVATIVE; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME INHIBITION; FEMALE; FLUORESCENCE MICROSCOPY; GROWTH INHIBITION; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NUDE MOUSE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; TUMOR GROWTH; TUMOR VASCULARIZATION; ANIMAL; ASCITES; CAPILLARY PERMEABILITY; DRUG ANTAGONISM; DRUG SCREENING; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE; VASCULARIZATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ASCITES; CAPILLARY PERMEABILITY; CELL LINE, TUMOR; CHROMONES; ENZYME INHIBITORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; MORPHOLINES; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 28144443723     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0206     Document Type: Article

References (22)

1. Adam RA, Adam YG. Malignant ascites: past, present, and future. J Am Coll Surg 2004;198:999-1011.
2. Beecham JB, Kucera P, Helmkamp BF, Bonfiglio TA. Peritoneal angiogenesis in patients with ascites. Gynecol Oncol 1983;15:142-5.
3. Gerber HP, McMurtrey A, Kowalski J, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3-kinase/ Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998;273: 30336-43.
4. Jiang BH, Zheng JZ, Aoki M, Vogt PK. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci U S A 2000;97: 1749-53.
5. Lal BK, Varma S, Pappas, PJ, Hobson RW, Duran WN. VEGF increases permeability of the endothelial cell monolayer by activation of PKB/Akt, endothelial nitric-oxide synthase, and MAP kinase pathways. Microvasc Res 2001;62:252-62.
6. Aramoto H, Breslin JW, Pappas PJ, Hobson RW, Duran WN. Vascular endothelial growth factor stimulates differential signaling pathways in in vivo microcirculation. Am J Physiol Heart Circ Physiol 2004;287: 1590-8.
7. Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 2000;6:880-6.
8. Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 2002;62:1087-92.
9. Shifren JL, Tseng JF, Zaloudek CJ, et al. Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis. J Clin Endocrinol Metab 1996;8: 13112-8.
10. Brader S, Eccles SA. Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. Tumori 2004;90:2-8.
11. Shayesteh L, Lu Y, Kuo WL, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999; 21:99-102.
12. Zhang L, Yang N, Katsaros D, et al. The oncogene phosphatidylinositol 3′-kinase catalytic subunit α promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma. Cancer Res 2003;63:4225-31.
13. Marti HH, Risau W. Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. Proc Natl Acad Sci U S A 1998;95:15809-14.
14. Tuder RM, Flook BE, Voelkel NF. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Fit in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest 1995;95:1798-807.
15. Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 2001;49:568-81.
16. Bancroft CC, Chen Z, Yeh J, et al. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-κ B and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 2002;99:538-48.
17. Mazure NM, Chen EY, Laderoute K, Giaccia AJ. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 1997;90:3322-31.
18. Fujio Y, Walsh K. Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J Biol Chem 1999; 274:16349-54.
19. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146: 1029-39.
20. Six I, Kureishi Y, Luo Z, Walsh K. Akt signaling mediates VEGF/VPF vascular permeability in vivo. FEBS Lett 2002;5322:67-9.
21. Jiang BH, Jiang G, Zheng JZ, et al. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 2001;12: 363-9.
22. Thakker GD, Hajjar DP, Muller WA, Rosengart TK. The role of phosphatidylinositol 3-kinase in vascular endothelial growth factor signaling. J Biol Chem 1999;274:10002-7.